Dissertations / Theses on the topic 'Plasma biomarker'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 dissertations / theses for your research on the topic 'Plasma biomarker.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.
Fisher, Christal. "Quantitative analysis of the plasma proteome in pre-eclampsia." Thesis, University of Manchester, 2012. https://www.research.manchester.ac.uk/portal/en/theses/quantitative-analysis-of-the-plasma-proteome-in-preeclampsia(3e207341-ebb9-4cb0-b7ea-34b9b110eda6).html.
Full textMohsenchian, Atefeh. "Biomarker discovery for ALS by using affinity proteomica." Thesis, KTH, Skolan för bioteknologi (BIO), 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-149440.
Full textGhobadi, Bita. "Suggestions for optimal biomarker miRNA extraction from plasma of sepsis patients." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18935.
Full textPapadia, Cinzia. "Plasma citrulline concentration : A biomarker of entercyte absorptive capacity in intestinal failure." Thesis, Imperial College London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.516555.
Full textVan, der Vaart Maniesh. "Characterization of circulating DNA as a biomarker for genetic aberrations in humans / Maniesh van der Vaart." Thesis, North-West University, 2006. http://hdl.handle.net/10394/1329.
Full textNI, JIAQIAN. "Plasma Biomarkers for Age-Related Macular Degeneration." Cleveland State University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=csu1236700270.
Full textCaranci, Giovanni. "Plasma alpha synuclein assay in Parkinson's disease and parkinsonisms." Doctoral thesis, Università di Catania, 2013. http://hdl.handle.net/10761/1322.
Full textXu, Haili, Timothy Radabaugh, Zhenqiang Lu, Michael Galligan, Dean Billheimer, Donata Vercelli, Anne L. Wright, Terrence J. Monks, Marilyn Halonen, and Serrine S. Lau. "Exploration of early-life candidate biomarkers for childhood asthma using antibody arrays." WILEY-BLACKWELL, 2016. http://hdl.handle.net/10150/621762.
Full textOda, Hiroki. "Plasma microRNAs Are Potential Biomarkers of Acute Rejection After Hindlimb Transplantation in Rats." Kyoto University, 2018. http://hdl.handle.net/2433/232087.
Full textTegg, Michelle. "Plasma insulin-degrading enzyme: Characterisation and evaluation as a potential biomarker for Alzheimer's disease." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2014. https://ro.ecu.edu.au/theses/1198.
Full textHakimi, Amirmansoor. "Plasma protein profiling for bladder cancer biomarker discovery using UPLC-HDMS^E label-free quantitation." Thesis, University of Leicester, 2013. http://hdl.handle.net/2381/28260.
Full textBourg, Pamela Wilkinson. "Development of a Plasma Biomarker to Test Oxidative Stress in Frail Elders with Traumatic Injury." Diss., The University of Arizona, 2016. http://hdl.handle.net/10150/612129.
Full textKawata, Keisuke. "SUBCONCUSSIVE HEAD IMPACT EFFECT ON PLASMA EXPRESSION OF S100-BETA AND PINCH PROTEINS IN COLLEGIATE FOOTBALL PLAYERS." Diss., Temple University Libraries, 2016. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/398688.
Full textPh.D.
In this prospective longitudinal investigation of Division-I collegiate football players, the acute and longer-term effects of repetitive subconcussive impacts on plasma S100β and PINCH levels and concussion-related symptom score were examined. The first aim was to investigate the acute repetitive subconcussive impact effect by comparing the biomarker levels at pre and post full-gear practice, followed by examining the relationship of head impact magnitude and frequency of on acute increases in S100β and PINCH levels and symptom score. Hypotheses for the first aim were that there would be acute increases in plasma S100β and PINCH levels, but no change would be observed in symptom score. A significant relationship between subconcussive impact kinematics and acute changes in outcome measurements would be observed only in S100β. The second aim was to examine the longer-term effect of subconcussive effects on plasma S100β and PINCH levels as well as symptom score compared to the pre-season baseline. It was hypothesized that the players who sustained high frequency and magnitude of subconcussive impact would induce chronically high levels of plasma PINCH compared to the baseline. However, chronic effect would not be found in plasma S100β and symptom score. Independent variables were time (pre vs. post-practice), days (baseline, 1st Pads-OFF, 1st Pads-ON, 2nd Pads-ON, 3rd Pads-ON, 4th Pads-ON, and post-season), and group (higher vs. lower impact group). Dependent variables were the plasma expression of S100β and PINCH and symptom scores at each time point, pre-post differences in the plasma expression of S100β and PINCH and symptom scores, and head impact kinematics (frequency, sum of peak linear and rotational acceleration). This prospective observational study of 22 Division-I collegiate football players included pre-season baseline, pre-season practices [1 helmet-only and 4 full-gear], and post-season follow-up. Acute subconcussive effects were examined using the data from the first full-gear practice. Cumulative subconcussive effects were examined across the study duration (total 12 time points per player). Blood samples and self-reported symptom scores were obtained and blood biomarkers were assessed for pre-post practices and pre-post season. Plasma S100β expression level was assessed using a sandwich-based enzyme-linked immunosorbent assay. Plasma PINCH expression level was assessed using western blot analysis. An accelerometer-embedded mouth guard was employed to measure impact kinematics including number of impacts (hits), peak linear acceleration (PLA), and peak rotational acceleration (PRA). For examining cumulative effects, based on the previously established cut-off value of 173.5 g, players who were exposed average impact magnitudes below 173.5 g per practice were categorized into lower (n = 8) or greater than 173.5 g were categorized into higher (n = 14) impact groups. Data analysis consisted of descriptive and inferential statistics. Student’s t-tests were used to assess group differences in demographic and head impact kinematic data, acute effects using pre-post practice change in concussion-related symptom scores and biomarker levels, and longer-term effects using pre-post season change in concussion-related symptom scores and biomarker levels. Pearson r correlations were used to examine potential relationship between acute increase in outcome measures and head impact kinematics data. Two-way repeated measures ANOVAs were used to identify cumulative subconcussive effects over time in concussion-related symptoms scores and biomarker levels. If necessary, one-way ANOVA as a function of group was used to identify where cumulative effect began compared to the baseline, using Dunnett’s host-hoc correction. The alpha level was set at p < 0.05. A total of 721 head impacts were recorded from the 22 players during the 5 training camp practices. There were significant differences in head impact kinematics per practice between lower and higher impact groups [number of impacts per practice, 1.3 vs. 10.0 (p < .001); linear acceleration, 36.4 vs. 285.6 g (p < .001); rotational acceleration, 2,048.4 vs. 16,497.31 rad/s2 (p < .001), respectively]. There were no changes in self-reported concussion symptoms across the study duration. While there was no change in longer-term effect between pre-season baseline and post-season follow-up in plasma S100β level, robust and acute increase was observed in post-full gear practice (0.111 + 0.01 ng/ml) compared to pre-practice S100β level, (0.048 + 0.01 ng/ml; p < .0001). The acute increase in plasma S100β was significantly and positively correlated to the number of hits (r = 0.636, p = 0.001), sum of peak linear acceleration (r = 0.570, p = .006), and sum of peak rotational acceleration (r = 0.655, p = 0.001) sustained. For plasma PINCH level, there was a 4-fold increase at post-practice compared to that of pre-practice (p = .037), indicating the acute effect of subconcussive impacts. However, the acute increase in plasma PINCH level was independent from frequency and magnitude of impacts sustained, demonstrated by no statistically significant correlations with the number of hits (r = 0.222, p = .333), sum of peak linear acceleration (r = 0.289, p = .204), and sum of peak rotational acceleration (r = 0.297, p = .191). When players were categorized into the lower and higher impact groups and assessed across the 5 training-camp practices, consistently higher levels of plasma S100β and PINCH were found only in the higher impact group at post-practice compared to the baseline. However, plasma level of S100β and PINCH at pre-practice remained stable from the baseline, suggesting the absence of chronic effect from repetitive head impacts. When season-long effects on plasma S100β and PINCH levels were examined, 10 out of 16 players showed increase in plasma PINCH level at post-season compared to the baseline (p = .039) while no significant difference in plasma S100β level. Results from the current study suggest that subconcussive head impacts do not exert self-claimed concussion-related symptoms; however, blood biomarkers detected noticeable acute changes following repetitive subconcussive impacts. Plasma level of S100β protein can be a potential diagnostic measurement to track acute brain burden, and plasma level of PINCH protein may be reflective of the longer-term cumulative brain damage from repetitive head impacts.
Temple University--Theses
ZILIOTTO, Nicole. "Genomic, vessel wall transcriptomic, and plasma proteomic approaches to investigate multiple sclerosis." Doctoral thesis, Università degli studi di Ferrara, 2019. http://hdl.handle.net/11392/2487975.
Full textQuesto studio è stato progettato per indagare attraverso diversi approcci sperimentali i geni e le proteine associate alla sclerosi multipla (SM), una malattia infiammatoria e demielinizzante del sistema nervoso centrale (SNC). L’obiettivo era individuare mediante indagini su pazienti, potenziali bersagli e biomarcatori per futuri studi meccanicistici. Mediante l'approccio genomico(cap.10), le famiglie selezionate sono state studiate attraverso WES per geni candidati da GWAS. Gli SNPs identificati a bassa frequenza sono stati ulteriormente studiati in pazienti indipendenti con SM. L’indagine ha rilevato varianti rare e nuove, tra cui le nulle della regione 3' di C6orf10 in combinazione con SNPs a bassa frequenza a livello intra ed extra locus, fornendo le basi per studi di espressione. L'approccio trascrittomico(cap.6) focalizzato sulla parete interna della vena giugulare, era supportato dall'interazione tra i meccanismi vascolari e quelli neurodegenerativi nella SM. Questa indagine ha prodotto una grande quantità di informazioni su diversi percorsi biologici e ha permesso l'analisi combinata trascrittoma-proteine. L'analisi a livello proteico è stata condotta nel plasma mediante saggi multiplex in relazione ai fenotipi clinici di SM e alle misure cerebrali MRI considerate come fenotipi quantitativi e "intermedi" della progressione della malattia. I livelli plasmatici più alti di CCL18 erano associati a caratteristiche neurodegenerative più gravi(cap.7). Il contributo delle molecole di adesione, suggerito dall'analisi trascrittomica, è stato esplorato in modo analogo(cap.8 e 9). La correlazione tra i livelli plasmatici di specifiche molecole di adesione nei pazienti ha evidenziato il processo di adesione dei leucociti nella malattia. L'aumento della permeabilità della barriera emato-encefalica, evento chiave nella fisiopatologia della SM, porta all’irruzione di fattori emostatici nel SNC, causando una risposta infiammatoria e l’attivazione immunitaria. I componenti dell'emostasi con le principali domande aperte in relazione alla SM sono stati investigati. Il FXII, la proteasi attivatrice della coagulazione da contatto trovata depositata nel cervello dei pazienti, potrebbe partecipare all'immunità adattativa durante la neuroinfiammazione. Nel plasma di pazienti(cap.4) i livelli di proteina del FXII erano superiori all'attività, causando un ridotto rapporto attività/antigene. I risultati corroborati dai saggi di generazione intrinseca di trombina, supporterebbero il contributo del FXII nella SM non attraverso la sua attività pro-coagulante. Lo studio di alcuni inibitori dell'emostasi (TFPI, ADAMTS13, HCII, TM) con proprietà antinfiammatorie, ha rivelato specifici schemi di correlazione(cap.5 e 11). L'associazione positiva di TFPI con TM, osservata nei pazienti e non in soggetti sani, implicherebbe che la perturbazione dell'endotelio agisca su più meccanismi di rilascio. Nei pazienti il PAI-1, l'inibitore chiave della fibrinolisi, era associato positivamente al FXII e negativamente all'HCII, suggerendo meccanismi patologici che influenzano la loro espressione in diversi tessuti con implicazioni nella generazione di fibrina e nella compromissione della fibrinolisi. Le correlazioni osservate tra i livelli plasmatici dei componenti dell'emostasi con le misure di MRI, non hanno superato la correzione per confronti multipli. La perdita extravascolare di sangue misurata come micro sanguinamenti cerebrali (MSC) attraverso MRI è stata studiata nei pazienti in relazione ai livelli plasmatici di componenti dell'emostasi. Livelli più bassi di ADAMTS13 sono stati rilevati nella coorte di SM ed in particolare nei pazienti con MSC(cap.5) che mostravano anche livelli più alti di VAP-1(cap.9). Queste nuove scoperte supportano l'analisi della proteasi ADAMTS13 e l’aminossidasi/proteina di adesione VAP-1 in relazione ai MSC. Questo studio fornisce nuovi biomarcatori della SM e potenziali bersagli farmacologici
Shenoy, Shamika. "Exosomal microRNA as a sepsis biomarker : Assessing different volumes of plasma for possible quantification of exosomal microRNA." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-17523.
Full textOmar, Jama Sukri. "Tau phosphorylation on threonine 217 as a potential biomarker for neurodegenerative diseases." Thesis, Högskolan i Borås, Akademin för textil, teknik och ekonomi, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:hb:diva-21321.
Full textHyperphosphorylation of the biomarker protein Tau occurs in many neurodegenerative diseases called Taupathies. The proteins main function in the human body is to modulate flexibility and stability for axonal microtubules. In Taupathies the hyperphosphorylation of the Tau triggers instability and neurodegeneration. Nowdays hyperphoshorylation on threonine 217 (P217) can only be measured in the brain. In this study the hyperphoshorylation on the phosphorylation site of threonine 217 (P217) is examined. In aim to see if levels of P217 is measurable in cerebrospinal fluid (CSF) and in blood. As well to evaluate how P217 variate in different Taupathies, through the use of brain samples from healthy controls and different Taupathies. The study is made for the purpose of enhancing the pure knowledge about the effect of hyperphosphorylation on threonine 217 in Taupathies and to contribute with a new sampling method for P217. Simoa HD-1 Analyzer was the key instrument of the analyses of P217. It’s an instrument which can detect abnormal levels of biomarkers through quantification, with help of antibodies and an enzyme. The enzyme is called Streptavidin β-galactosidase and converts an existing P217 molecule in the samples to a fluoresce product. Through the use of Simoa HD-1 Analyzer an ultrasensitive assay with antibodies P217 and Tau 12 was developed which could detect very low levels of P217 in brain, CSF and in blood. Variation of P217 levels was also found in different Taupathies. The Taupathies with the highest levels of P217 was Progressive supranuclear palsy, Corticobasal Degeneration and Globular glial Taupathies.
Yu, Xinwei. "Immunoglobulin G N-glycan profiling as a risk stratification biomarker for type 2 diabetes." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2019. https://ro.ecu.edu.au/theses/2199.
Full textDing, Juan. "A Proteomic Approach to Identify Biomarkers for Growth Hormone and Aging." Ohio University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1250622748.
Full textDeziderio, Leandro Aparecido Grange. "Extração das isoformas da proteína precursora do amilóide em plasma rico em plaquetas para testes proteômicos como biomarcador da doença de Alzheimer." Universidade de São Paulo, 2008. http://www.teses.usp.br/teses/disponiveis/75/75132/tde-24082009-165818/.
Full textThe goal of this Master\'s work was to develop an analytical methodology focused on protein sample preparation. The analyte studied were soluble amyloid precursor protein isoforms (APPs) which has been studied in many groups in Brazil and around the world as a possible biomarker for Alzheimer\'s disease. Sample preparation is a crucial step that influence significantly on next results, especially about biological samples which require more attention. For the best sample preparation for APPs, was used SDS-PAGE and protein electrotransference by Western Blotting techniques. The efficiency of the sample preparations was evaluated based on specific antibody reactions and densitometry measures of these interactions. After that, the APP isoforms were analyzed by two dimensional electrophoresis (2DE). During the sample preparation, were obtained unexpected molecular mass results, which indicated some APPs biodegradation. For the determination of the interference source, the variants steps of the sample preparation were analyzed. The sample preparation interference source was identified, but a more detailed study of the isoforms (by mass spectrometry) was not possible as well as the analysis of the identity of the possible fragmented isoforms.
Kranawetvogl, Andreas [Verfasser], and Franz [Akademischer Betreuer] Worek. "Untersuchung neuartiger Disulfid-Addukte aus humanem Plasma als Biomarker zum Nachweis einer Vergiftung mit phosphororganischen Cholinesteraseinhibitoren / Andreas Kranawetvogl ; Betreuer: Franz Worek." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2019. http://d-nb.info/1188200631/34.
Full textIguchi, Kota. "Chronological profiling of plasma native peptides after hepatectomy in pigs: Toward the discovery of human biomarkers for liver regeneration." 京都大学 (Kyoto University), 2017. http://hdl.handle.net/2433/225465.
Full textSaarnio, J. (Juha). "Distribution of carbonic anhydrase IX, MN/CA IX, in normal and neoplastic gastrointestinal and hepatobiliary tissues:its potential value as a new biomarker and comparison of its expression with that of isoenzymes I, II, IV, V, and VI." Doctoral thesis, University of Oulu, 2000. http://urn.fi/urn:isbn:9514257901.
Full textByström, Sanna. "Affinity assays for profiling disease-associated proteins in human plasma." Doctoral thesis, KTH, Proteomik och nanobioteknologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-202616.
Full textQC 20170302
Klein, Katharina [Verfasser], and Frank [Akademischer Betreuer] Kolligs. "Prognostische und therapeutische Rolle von HPP1 als molekularer Biomarker im Plasma von Patienten mit metastasiertem kolorektalem Karzinom / Katharina Klein ; Betreuer: Frank Kolligs." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2020. http://d-nb.info/1206096454/34.
Full textLogeeshan, Velmanickam. "Implementation of Low Cost, High-Throughput and High Sensitive Biomarker Detection Technique in Serum/Plasma Samples by Integrating Dielectrophoresis and Fluorescence Based Platform." Diss., North Dakota State University, 2019. https://hdl.handle.net/10365/29893.
Full textLaube, Heli [Verfasser]. "Plasma VEGF-Konzentration als Biomarker eines kompetenten Brain-pulls: seine Veränderungen nach Mahlzeit- und CRH-Stimulation bei normalgewichtigen und adipösen Probanden / Heli Laube." Lübeck : Zentrale Hochschulbibliothek Lübeck, 2011. http://d-nb.info/1015756883/34.
Full textGiebel, Gerald Kraft Max Ernst [Verfasser], and Marcus [Akademischer Betreuer] Unger. "Quantitative Analyse von neuroendokrinen Peptiden als potentielle Biomarker im Liquor und Plasma von Parkinson Patienten und Kontrollpersonen / Gerald Kraft Max Ernst Giebel ; Betreuer: Marcus Unger." Saarbrücken : Saarländische Universitäts- und Landesbibliothek, 2017. http://d-nb.info/1173163131/34.
Full textSerra, Matamala Isabel. "Estudi del perfil proteic del plasma de pacients amb diferents graus d’hepatopatia: identificació de biomarcadors del carcinoma hepatocel·lular." Doctoral thesis, Universitat Autònoma de Barcelona, 2016. http://hdl.handle.net/10803/381070.
Full textHepatocellular carcinoma (HCC) is the main cause of death in cirrhotic patients. For that reason, these patients are included in a surveillance program with abdominal ultrasonography twice per year to detect HCC at early tumour stages, when cure is highly likely. Nevertheless, only 40% of the cases are diagnosed at early stages and the HCC recurrence rate after curative treatment -surgical resection or percutaneous ablation- is very high. Therefore, the identification of biomarkers is needed to use them as complementary tools for surveillance and for predicting tumour recurrence after treatment. The main aim of this thesis is to perform proteomic profiling of the plasma of cirrhotic patients with and without HCC to identify diagnostic and invasiveness biomarkers. We analysed the protein profile of 30 plasma samples from 12 selected liver disease patients with different grade of fibrosis (mild fibrosis n=3, cirrhotic Child-Pugh A n=7 and Child-Pugh B n=2), 15 HCC patients (BCLC 0/A, n=9; BCLC C/D with portal thrombosis and/or metastasis, n=6) and 3 healthy voluntaries. Plasma samples were depleted of 20 most abundant interfering proteins fractionated by unidimensional electrophoresis and enzymatically digested, and peptides were analysed by liquid chromatography coupled with mass spectrometry (HPLC-MS/MS). We identified a panel of 31 early diagnostic biomarkers by comparing the plasma proteome of cirrhotic patients with early HCC versus those without HCC and a panel of 41 biomarkers related to tumour invasiveness HCC as compared to early cases. Pathway analysis of the differentially proteins by Ingenuity Pathway Analysis revealed vital canonical pathways involving acute phase response and nitric oxide production signalling and LXR/RXR activation specially in advanced HCC. Furthermore, differentially plasma proteins in advanced HCC suggest activation of MYC, VEGF, HGF and HNF1A as upstream regulators. Interestingly, 79% of identified biomarkers have been already reported in HCC and other cancer. Finally we validate the plasma levels of 2 out 7 biomarker candidates selected by enzyme-linked immunosorbent assays (ELISA). In conclusion we have been able to identify a panel of diagnostic and prognostic biomarkers of HCC by plasma protein analysis. Once validated in an independent cohort, our plasma-based biomarker panels could be used as complementary tools to improve the clinical management of HCC patients.
Neiman, Maja. "Bead based protein profiling in blood." Doctoral thesis, KTH, Proteomik, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-117960.
Full textQC 20130208
Monteiro, Anita-Ann. "Detection of exosomal mirna from different volumes of biofluids as biomarkers for the diagnosis of sepsis : Future diagnostics of sepsis." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-17592.
Full textHubel, Silvia [Verfasser]. "Untersuchung der Biomarker Interferon-gamma induziertes Protein 10 (IP-10) und CXC-Motiv-Chemokinrezeptor 3 (CXCR3) im Plasma nierentransplantierter Patienten in den ersten fünfzehn Monaten nach Transplantation / Silvia Hubel." Tübingen : Universitätsbibliothek Tübingen, 2020. http://d-nb.info/1218073640/34.
Full textFarthing, Don E. "INVESTIGATION OF INOSINE AND HYPOXANTHINE AS BIOMARKERS OF CARDIAC ISCHEMIA IN PLASMA OF NON-TRAUMATIC CHEST PAIN PATIENTS AND A RAPID ANALYTICAL SYSTEM FOR ASSESSMENT." VCU Scholars Compass, 2008. http://hdl.handle.net/10156/1510.
Full textDubois, Christelle. "Confirmation de biomarqueurs pour le pronostic du sepsis et développement de tests rapides High plasma level of S100A8/S100A9 and S100A12 at admission indicates a higher risk of death in septic shock patients Top-down and bottom-up proteomics of circulating S100A8/S100A9 complexes in plasma of septic shock patients." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS521.
Full textSepsis is the 3rd leading cause of death in Western countries, with a mortality rate between 20 and 50% depending on the severity. The 'prediction' of the patient's clinical outcome is essential to establish the most appropriate treatment. Some inflammation or infection markers protein (CRP, procalcitonin) are cited for clinical follow-up of patients but lack specificity for sepsis. On the other hand, "omics" studies have generated lists of potential biomarkers of sepsis prognosis. However, none have yet been validated and/or confirmed based on the severity of the sepsis and the patient's fate. This requires access not only to fully characterized patient cohorts but also to robust and validated quantitative methods. Mass spectrometry provides a high level of specificity and high multiplex capacity and that would allow to confirm the interest of one or more of these proteins for sepsis prognosis. Immunological assays provide, in addition to sensitivity and specificity, a simple and rapid routine clinical implementation. First, a list of biomarkers identified with patient cohorts was established from the literature. Then, methods to quantify these candidate biomarkers were developed. On the one hand, we have been interested in quantifying calgranulins in plasma by developing ELISAs and mass spectrometry methods using bottom-up and top-down approaches. On the other hand, two multiplex quantification methods by mass spectrometry with and without immunopurification step according to protein concentrations have been developed to verify the relevance of the list of potential biomarkers. All these methods were applied to a cohort of 49 patients with septic shock
Hasanova, Reyhan. "Identification de nouveaux biomarqueurs des cancers colorectaux." Thesis, Bourgogne Franche-Comté, 2019. http://www.theses.fr/2019UBFCE017.
Full textColorectal cancer (CRC) is the third most commonly diagnosed cancer after lung cancer, and prostate cancer. The early prognostic estimation could reduce the mortality and the implementation of new biomarkers is getting indispensable. In this study we investigated two molecules for better characterization and prognosis of CRC: Angiopietin2 (Ang2) and Mesothelin (Msln). We first analyzed transcriptomic and clinicopathological data of primary tumors collected from online repositories. 1617 transcriptomes had been produced by microarrays and were downloaded from NCBI Gene Expression Omnibus (GEO) and additionally 573 RNAseq transcriptomic data were collected from The Cancer Genome Atlas (TCGA) repository. Plasma ELISA assays for Ang2 and Msln were then performed in 20 healthy donors and in 51 CRC patients from a local cohort in order to validate those proteins as potential biomarkers. Ang2 survival analyses performed on transcriptomic data showed that high intratumoral Ang2 expression was associated with poor overall survival (OS) and relapse-free survival (RFS) in CRC patients with localized stages. As expected, Ang2 expression was associated with stroma infiltration and angiogenesis but multivariate analyses showed that Ang2 was an independent factor for OS after adjusting it with all available variables (including Consensus Molecular Subtypes of CRC). The plasma measurement of Ang2 showed that the metastatic CRC (mCRC) patients had higher levels than the healthy donors and the progression free survival (PFS) was lower in patients with higher Ang2. High intratumoral MSLN expression in CRC transcriptomes was associated with poor OS and RFS. It was also an independent factor for OS and RFS. Pathway analyses revealed that Msln expression was associated with tumor exosome pathway and cell invasion. ELISA measurements of Msln levels showed that the patients with colorectal cancer had significantly higher Msln levels than healthy donors. Furthermore, the CRC patients with increased levels of Msln had poor OS than the patients with low Msln levels. Taken together, these results suggest that both Ang2 and Msln are independent prognostic biomarkers for CRC. We now aim to stratify risk using both Ang2 and Msln to improve the treatment of CRC patients
Drobin, Kimi. "Antibody-based bead arrays for high-throughput protein profiling in human plasma and serum." Licentiate thesis, KTH, Proteinvetenskap, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-225980.
Full textQC 20180412
Chu, Ling-fung, and 朱凌峯. "Plasma inflammatory biomarkers in stable COPD patients." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48333682.
Full textpublished_or_final_version
Medicine
Master
Master of Medical Sciences
Walsh, Kyle B. "Plasma Biomarkers for Ischemic and Hemorrhagic Stroke Diagnosis." University of Cincinnati / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1511859455574062.
Full textCreegan, Rhona. "Identification of plasma lipid biomarkers in Alzheimer's disease." Thesis, Edith Cowan University, Research Online, Perth, Western Australia, 2014. https://ro.ecu.edu.au/theses/1340.
Full textJohnsson, Anna. "Mining for Lung Cancer Biomarkers in Plasma Metabolomics Data." Thesis, Linköping University, Biotechnology, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-57670.
Full textLung cancer is the cancer form that has the highest mortality worldwide and inaddition the survival of lung cancer is very low. Only 15% of the patients are alivefive years from set diagnosis. More research is needed to understand the biologyof lung cancer and thus make it possible to discover the disease at an early stage.Early diagnosis leads to an increased chance of survival. In this thesis 179 lungcancer- and 116 control samples of blood serum were analyzed for identificationof metabolomic biomarkers. The control samples were derived from patients withbenign lung diseases.Data was gained from GC/TOF-MS analysis and analyzed with the help ofthe multivariate analysis methods PCA and OPLS/OPLS-DA. In this thesis it isinvestigated how to pre-treat and analyze the data in the best way in order todiscover biomarkers. One part of the aim was to give directions for how to selectsamples from a biobank for further biological validation of suspected biomarkers.Models for different stages of lung cancer versus control samples were computedand validated. The most influencing metabolites in the models were selected andconfoundings with other clinical characteristics like gender and hemoglobin levelswere studied. 13 lung cancer biomakers were identified and validated by raw dataand new OPLS models based solely upon the biomarkers.In summary the identified biomarkers are able to separate fairly good betweencontrol samples and late lung cancer, but are poor for separation of early lungcancer from control samples. The recommendation is to select controls and latelung cancer samples from the biobank for further confirmation of the biomarkers.NyckelordLung cancer is the cancer form that has the highest mortality worldwide and inaddition the survival of lung cancer is very low. Only 15% of the patients are alivefive years from set diagnosis. More research is needed to understand the biologyof lung cancer and thus make it possible to discover the disease at an early stage.Early diagnosis leads to an increased chance of survival. In this thesis 179 lungcancer- and 116 control samples of blood serum were analyzed for identificationof metabolomic biomarkers. The control samples were derived from patients withbenign lung diseases.Data was gained from GC/TOF-MS analysis and analyzed with the help ofthe multivariate analysis methods PCA and OPLS/OPLS-DA. In this thesis it isinvestigated how to pre-treat and analyze the data in the best way in order todiscover biomarkers. One part of the aim was to give directions for how to selectsamples from a biobank for further biological validation of suspected biomarkers.Models for different stages of lung cancer versus control samples were computedand validated. The most influencing metabolites in the models were selected andconfoundings with other clinical characteristics like gender and hemoglobin levelswere studied. 13 lung cancer biomakers were identified and validated by raw dataand new OPLS models based solely upon the biomarkers.In summary the identified biomarkers are able to separate fairly good betweencontrol samples and late lung cancer, but are poor for separation of early lungcancer from control samples. The recommendation is to select controls and latelung cancer samples from the biobank for further confirmation of the biomarkers.Nyckelord
Correia, Marta Sofia da Silva. "Identification of potential Alzheimer’s disease biomarkers in plasma using FTIR." Master's thesis, Universidade de Aveiro, 2014. http://hdl.handle.net/10773/13622.
Full textCurrent clinical AD diagnosis criteria used to identify the disorder in patients who have already overt the advanced stage of dementia. This is too late for some kind of successful disease adjustment and consequently, early recognition of AD needs to be improved. Therefore, it is really needed different approaches for discovering new AD biomarkers, such as the application of metabolomics techniques (e.g. FTIR). The potential of FTIR in the clinical field has recently received particular attention, since it uses vibration frequencies of molecules present in the analysed sample to produce a metabolic fingerprint, which is then specific for each sample. This dissertation aims to identify biochemical alterations that might be related to dementia, being possible to distinguish between control and disease groups of plasma samples, through application of FTIR methodology at the 4000-600 cm-1 spectral region. Using plasma samples makes the process being minimally invasive, with other relevant clinical advantages. Besides the collection of blood samples used in this project, the volunteers were also submitted to cognitive evaluation trough Mini Mental State Examination (MMSE) and Clinical Dementia Rating (CDR), with other relevant clinical information being also collected. All the analysed samples were matched by age and sex. For a better discrimination between control and disease samples, Principal Component Analysis (PCA) was applied to spectra data at specific regions, namely 3500-2700 cm-1, 1700-1400 cm-1, and 1200-900 cm-1. This allowed to identify the main pathological changes that occurred at the biochemical level during neurodegenerative disorder development. In the former spectral region, disease samples presented a higher content of saturated lipids in relation to the unsaturated ones, which translates in a high potential brain damage. Besides, it was also noted the presence of carboxylic acids that are usually related to lipid hyperoxidation, production of reactive carbonyls and proteins structural and functional alterations. In turn, the spectral region 1700-1400 cm-1 allowed to identify differences in protein conformation between control and disease samples, and these last ones were still related with occurrence of protein aggregates. In other hand, the 1200-900 cm-1 region could be associated to cellular damage provoked by oxidative stress in disease samples. As an important note to take, FTIR analysis could have the potential to be applied in future not only for cognitive impairment diagnosis but also for identification of disease stage and prognostic evaluation, besides assessment of disease developing risk for control subjects.
Os atuais critérios clínicos de diagnóstico da doença de Alzheimer geralmente identificam a patologia apenas quando os pacientes já atingiram a fase de demência, ou seja, o estágio mais avançado da doença. Isto revela-se demasiado tarde para que qualquer tipo de terapêutica seja bem-sucedida e, consequentemente é necessário desenvolver uma metodologia de diagnóstico que permita um reconhecimento mais precoce da doença. Desta forma, é preciso adotar diferentes abordagens para a descoberta de novos biomarcadores para a doença de Alzheimer, tais como a utilização de técnicas de metabolómica (ex. FTIR). O potencial do FTIR no campo clínico recebeu recentemente particular atenção, sendo que esta técnica utiliza as frequências de vibração das moléculas presentes na amostra analisada para produzir uma “impressão digital” metabólica, a qual é específica para cada amostra. Esta dissertação tem como objetivo a identificação de potenciais alterações bioquímicas que possam estar relacionadas com demência, tornando possível a distinção entre grupos controlo e de doentes no seio do conjunto de amostras de plasma analisadas. A utilização de amostras de plasma torna o processo minimamente invasivo, de entre outras vantagens clínicas. Para além da colheita das amostras de sangue utilizadas neste projeto, os voluntários foram submetidos a uma avaliação cognitiva através da realização do MMSE e do CDR, com outra informação clínica relevante a ser também recolhida. Todas as amostras analisadas foram emparelhadas de acordo com a idade e o sexo. Para uma melhor distinção entre amostras controlo e de doentes foi aplicada a metodologia de PCA aos dados dos espectros obtidos em regiões específicas, nomeadamente em 3500-2700 cm-1, 1700-1400 cm-1, e 1200-900 cm-1. Isto permitiu identificar as principais alterações patológicas que ocorrem a nível bioquímico durante o desenvolvimento da doença neurodegenerativa. Na primeira região espectral referida, as amostras dos doentes apresentaram um maior conteúdo de lípidos saturados comparativamente aos não saturados, o que se traduz num potencial risco cerebral maior. Para além disso, foi observada a presença de ácidos carboxílicos, usualmente relacionados com hiperoxidação de lípidos, produção de carbonilos reativos e alterações estruturais e funcionais de proteínas. Por sua vez, a região espectral 1700-1400 cm-1 permitiu identificar diferenças na conformação de proteínas entre amostras controlo e de doentes, tendo estas últimas sido ainda relacionadas com a ocorrência de agregados proteicos. Por outro lado, a região 1200-900 cm-1 pôde ser relacionada com presença de danos celulares provocados por stress oxidativo nas amostras de doentes. Como importante nota a reter, a análise por FTIR pode ter o potencial para ser aplicada no futuro não apenas para diagnóstico de disfunção cognitiva, mas também para identificação do estádio da doença e realização de prognósticos, para além da avaliação do risco de desenvolvimento da doença em sujeitos controlo.
MARTINEZ, FERNANDEZ ALMA ESTEFANIA. "ANALYSIS OF LIPID AND PROTEIN OXIDATION STATUS IN HEART FAILURE PATIENTS." Doctoral thesis, Università degli Studi di Milano, 2020. http://hdl.handle.net/2434/700135.
Full textHoward, James W. "The development of mass spectrometry-based methodologies for the high throughput quantitation of peptides in biological matrices." Thesis, Loughborough University, 2018. https://dspace.lboro.ac.uk/2134/32454.
Full textde, Cal Massimo. "Sepsis and AKI in ICU Patients: the role of Plasma Biomarkers." Doctoral thesis, Università degli studi di Padova, 2012. http://hdl.handle.net/11577/3421725.
Full textLa sepsi è una delle cause principali di morbidità e mortalità nei pazienti critici in Terapia Intensiva. I batteri Gram-negativi sono implicati nel 50-60% dei casi di sepsi in Terapia Intensiva e l’endotossina svolge un ruolo importante nella patogenesi dello shock settico. La sepsi è anche un fattore che contribuisce in oltre il 20% dei casi al danno renale acuto nei pazienti in terapia intensiva, e in alcuni casi vi è la necessità di una terapia renale sostitutiva. L’insufficienza renale acuta (IRA) si verifica nel 35-65% dei ricoveri in Terapia Intensiva e la maggior parte degli studi mostrano un aumento di cinque volte sul rischio di morte tra i pazienti con danno renale acuto rispetto ai pazienti senza IRA. Dato il tasso di mortalità più elevato di pazienti in Terapia Intensiva con sepsi e IRA, si è indagato nei pazienti settici della Terapia Intensiva sulla possibile correlazione tra i biomarcatori di danno d'organo (NGAL, AOPP e BNP) e l'attività dell’endotossina. Inoltre, il confronto dei livelli di questi marcatori sono stati analizzati tra i pazienti settici e non settici, pazienti settici con o senza IRA e tra i pazienti che hanno sviluppato danno renale acuto, con o senza sepsi. Novantotto pazienti adulti ricoverati in Terapia Intensiva dell'Ospedale di San Bortolo, Vicenza, Italia, tra ottobre 2008 e agosto 2010, sono stati arruolati in questo studio. I pazienti sono stati divisi in due gruppi a seconda della presenza di sepsi, definita come Sindrome da Risposta Infiammatoria Sistemica (SIRS) associata a un processo infettivo. Cinquantasei pazienti presentavano sepsi, mentre 42 pazienti non presentavano sepsi. Tra i pazienti settici, 24 soggetti hanno sviluppato IRA, definita dai criteri RIFLE, mentre 32 non hanno IRA. Una correlazione significativa tra l’attività di endotossina e i biomarcatori è stata trovata solo con i livelli di BNP dei pazienti settici (p=0,02). I livelli di NGAL, BNP e AOPP erano significativamente più alti tra i pazienti settici rispetto ai soggetti non settici (p<0,001). Tra i pazienti settici, i soggetti che hanno sviluppato IRA hanno mostrato livelli più alti di NGAL e AOPP (p=0,0425), e BNP (p=0,0327). La correlazione tra l'attività dell’endotossina e i livelli di BNP nei pazienti settici, e l'aumento dei livelli di NGAL, BNP e AOPP in caso di sepsi e IRA, in particolare se sono associati, indicano un coinvolgimento multiorgano in queste condizioni. La loro valutazione può permettere ai medici di individuare prima i pazienti a maggior rischio di morbidità e mortalità.
Ding, Juan. "A proteomic approach to identify biomarkers of growth hormone and aging." View abstract, 2009. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&res_dat=xri:pqdiss&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&rft_dat=xri:pqdiss:3372300.
Full textSeuma, Morlanes Jaime. "Analysis of protein biomarkers by inductively coupled plasma mass spectrometry linked immunoassay." Thesis, University of Sheffield, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.538004.
Full textXu, Haili. "Discovery And Validation Of Early Life Plasma Protein Biomarkers For Childhood Asthma." Diss., The University of Arizona, 2014. http://hdl.handle.net/10150/333486.
Full textMurata, Koichi. "Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis." Kyoto University, 2013. http://hdl.handle.net/2433/174785.
Full textEncarnação, Joana. "Impact of coffee-consuming habits on plasma biomarkers in a healthy adult population." Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/9707/.
Full textQundos, Ulrika. "Antibody based plasma protein profiling." Doctoral thesis, KTH, Proteomik och nanobioteknologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-126270.
Full textQC 20130821
Jin, Yan Nan. "Plasma phytochemicals : mediators of CVD risk reduction and biomarkers of fruit and vegetable intake." Thesis, University of Reading, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.578030.
Full text